Introduction
The mainstay of adjuvant treatment in patients with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2−) early-stage breast cancer (BC) is endocrine therapy. Chemotherapy is not recommended for all patients, because some have a more favorable prognosis and benefit less from chemotherapy.
However, predictive models based only on clinical and histochemical features have not been shown to accurately identify which patients benefit from adjuvant chemotherapy. 1 Thus, in recent years, genomic tests with a strong prognostic and predictive power have been developed. 2 The 21-gene recurrence score (RS) for early-stage BC (Oncotype DX; Genomic Health, Redwood City, CA, USA) is based on a reverse transcriptase polymerase chain reaction assay of 5 reference genes and 16 cancer-related genes associated with cell proliferation, invasion, and hormone response. 3 It became commercially available in 2004 and uses a continuous scale (from 0 to 100) to predict 10-year cancer recurrence risk and benefit of adjuvant chemotherapy in patients with early-stage ER+, lymph node-negative disease. That score is subdivided into 3 risk categories: low, intermediate, and high. 3, 4 Its impact on the decision-making process for adjuvant therapy in patients with ER+ and HER2− BC was addressed in different studies, 4, 5 which determined its inclusion in clinical guidelines. [6] [7] [8] However, other experts, like those in the Evaluation of Genomic Applications in Practice and Prevention group, believe that there is no definitive evidence demonstrating the test's utility as a predictive tool of the benefit of adjuvant chemotherapy. 9 The Basque Health Service (Osakidetza) included the 21-gene RS test in its portfolio in September 2012, and its real-life application meant a possible change in the final treatment decision for patients needing evaluation.
The main objective of the study was to carry out an economic evaluation by measuring the assay's incremental short-term budget impact. The second objective was to measure the probability of a treatment change due to the use of the 21-gene RS when compared to treatment based on the use of clinical criteria alone.
Methods
This study was an observational, prospective, multicenter study to assess the impact of Oncotype DX-RS test use on adjuvant chemotherapy decision making and was carried out in 4 hospitals within the Basque Health Service (Basurto, Donostia, Onkologikoa, and Araba hospitals) between September 1, 2012, and September 30, 2015. Inclusion criteria were the following: 1) operable earlystage BC and adequate surgery performed for primary tumor; 2) ER+/HER2−; and 3) pathological TNM (TNM): pT1b, if at least 2 of the following 3 factors were present: histologic grade (G) III, Ki-67 ≥14% and lymphovascular invasion; pT1c, all except those with both GI and Ki-67 <14%; pT2, all except those with GIII; pN0 or 1mi; and M0. The pT criteria, although arbitrary, were established by the group of experts from the Basque Country Health System by consensus to optimize the economic cost of the test and perform it when the decision to administer chemotherapy was less clear. Exclusion criteria were as follows: 1) patient's refusal to undergo the assay; 2) patient's refusal to receive chemotherapy; and 3) contraindication for chemotherapy (elderly patients and concomitant diseases).
The recommendation of adjuvant systemic therapy, only endocrine therapy or chemotherapy plus endocrine therapy, was recorded before (based on conventional clinicopathologic factors) and after the result of the test. The recommendation for chemotherapy based on clinicopathologic factors was pT2 (all) and pT1c if at least 1 of 2 factors was present (high Ki-67, GIII); no chemotherapy was recommended for pT1a-b. The recommendation after the test was as follows: 1) if RS was low (<18), no chemotherapy was recommended; 2) if RS was high (≥31), chemotherapy was recommended; and 3) if RS was intermediate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , the recommendation took into account the clinicopathologic factors and remained unchanged. The final treatment the patient received was also recorded and was performed according to the final patient choice. The study protocol was approved by the Basque Country Central Ethics Committee.
All data for the variables in the study were collected by each participating medical oncologist in an anonymized manner in a specific database. First, the clinician completed a pretest questionnaire to establish the recommended initial treatment according to standard clinical criteria. The following clinical features were recorded: age, TNM classification, ERs, progesterone receptors (PRs), Ki-67, 10 tumor size, tumor grade, surgery type, type of diagnostic (detected at screening program, interval cancer, or outside screening program), and intrinsic subtype according to Prat's classification and menopause status. 11 Variables related to the test such as the RS, the pretest and posttest treatment recommendations (endocrine therapy vs endocrine plus chemotherapy), and final treatment choice were also collected. Follow-up data included recurrence, recurrence data, type of recurrence, last contact, and last contact condition (alive without disease, alive with disease, dead from BC, and dead from other causes), but they were not included in this study, given its short-term approach. The RSs were classified into 3 levels of risk: low (RS <18), medium (RS ≥18<31), and high (RS ≥31). These cutoff points were chosen based on the results of the National Surgical Adjuvant Breast and Bowel Project Protocol B20. 3 The economic assessment included the resource use in terms of chemotherapy, first and successive consultations, and adverse effects. 12 However, we used standard logistic regression as our aim was to explore the change in the predictive capacity of certain variables to identify which patients should receive chemotherapy. Furthermore, we used a complementary approach based on receiver operating characteristic (ROC) curves to measure the discriminative ability of Ki-67, tumor size, and PR to identify which patients would receive chemotherapy based on the 21-gene RS test. 13, 14 ROC curves determined whether a diagnostic test identified the condition of interest (chemotherapy treatment) and were obtained by plotting sensitivity for each break point on the y-axis and its corresponding 1 -specificity on the x-axis. If the test was sensitive, the ROC curve had sensitivity peaks with associated minimum values of 1 -specificity. Conversely, if the test was nonsensitive, the ROC curve was near the reference line (diagonal line dividing the axis quadrant into 2 equal parts), which indicated the minimum level of discrimination. To characterize the test as a discriminant, areas >70% were required. 13, 14 All statistical analyses were performed by using SPSS Version 23 (IBM Corporation, Armonk, NY, USA).
Cost analysis
The base case short-term budget impact analysis was carried out from the perspective of the public health system; therefore, only the health care costs were included, but a complementary societal approach was also used. 15, 16 Resource consumption was recorded prospectively from the beginning of the decision-making process until the end of treatment in terms of visits, chemotherapy, and hospitalizations caused by the chemotherapy toxicity. Treatment decisions about endo- crine therapy and chemotherapy prescription were recorded before and after the clinicians received the results of the 21-gene RS testing. Total costs of chemotherapy (ie, chemotherapy drugs, concomitant medications such as granulocyte colony-stimulating factor [G-CSF], administration cost, and follow-up medical visits) were calculated by multiplying resource consumption by unit costs. This cost estimate included only short-term costs associated with chemotherapy treatment; it did not incorporate long-term costs such as longterm side effects. This cost estimate, therefore, constitutes a conservative estimate of the real cost of chemotherapy to the Basque Health Service.
All unit costs were adjusted to 2014 and are displayed in Tables S1 and S2. The hospital admission cost was calculated by the analytical accounting system of the Basque Health Service and the diagnosis-related group system. Unit costs for pharmacy, outpatient visits, emergency room visits, and outpatient clinic service were retrieved from the same accounting system. The costs of adverse effects were calculated by multiplying the frequency of the event by the unit cost. The actual price for the 21-gene RS test to the regional health care payer in Basque Country in 2014 (€2,620) was communicated by the Spanish distributor itself. Given the uncertainty about certain parameters, we carried out a sensitivity analysis by changing the unit costs for chemotherapy and test cost by ±20%. We also reviewed the economic impact of the range of decision-change percentages in single hospitals.
In addition to the health service perspective, the societal perspective was applied to address the consequences of chemotherapy on patient sick leave. The patient's time lost due to health problems should be independently quantified when it is likely to have a significant economic impact. 15, 16 In this case, the lost time as paid work was addressed from the perspective of human capital, where the work time lost due to illness was the outcome measure. 15, 16 Thus, the societal perspective was applied by measuring the potential impact of productivity loss. 17 The unit cost for productivity loss for each patient was estimated from the Spanish average monthly gross salary in 2014 (€1,881/month) 18 and the length of the treatment for each chemotherapy regimen.
Informed consent
The study protocol was approved by the Euskadi Ethical Committee (PI2015185). Patients gave their signed informed consent when required and applicable according to the Ethic Committee Review Board. The research was conducted in accordance with the Declaration of Helsinki (1975).
Results
The 21-gene RS test was used to evaluate 401 cases of BC. Table 1 lists the patient and tumor characteristics: low (54.6%), intermediate (38.5%), and high (6.9%). One third of the patients were aged <50 years; the mean age was 57 years, and most patients were postmenopausal (64.5%). The group with largest tumor size corresponded to T1c (65.1%). Consistent with our results, chemotherapy would have been prescribed to 56% of patients based on conventional clinicopathologic factors, and that percentage would have decreased to 25% with RS testing. Table 2 summarizes the treatment recommendations and treatment shift between pre-and post-RS. The initial chemoendocrine recommendation was changed to an endocrine recommendation for 124 individuals (31%).
On the ROC curve (Figure 1 ), PRs and Ki-67 appeared to be accurate predictors of chemotherapy use when decision making was based on the 21-gene RS, because their area under the curve values were >0.70 (Table S3 ). The results of the logistic regressions (Table 3) reinforce the different roles of PR and tumor size in the effect of the ROC curve. Only Ki-67 showed significant odds ratios in both logistic regressions. Table 4 displays the disaggregated short-term budget impact with and without 21-gene RS testing distributed by chemotherapy regimen. On the one hand, there was an increase in the total cost per patient due to the cost of the 21-gene RS assay. On the other hand, the decision shift in adjuvant treatment resulted in a reduction in the total number of cases requiring chemotherapy. Thus, the inclusion of the test led to a reduction in overall chemotherapy costs (€369,740). Given the estimated cost of €2,620 per test, there were no net savings, as the difference in chemotherapy treatment did not entirely offset the test cost. However, when a societal perspective was taken into account, the overall budget impact of the 21-gene RS test was cost-neutral, as the savings in chemotherapy costs, in addition to the savings in productivity loss, were greater than the incremental costs due to testing. The total net cost associated with sick leaves was estimated to be €792,780, and the reduction in productivity loss per patient was €1,977. Table S4 disaggregates productivity losses according to the type of chemotherapy. The sensitivity analysis (Table 5) showed no relevant change in the impact according to the perspective. The societal perspective revealed a higher cost only when the test price was increased.
Discussion
The use of the 21-gene RS test has significantly changed the indication for chemotherapy in our group of patients with BC ER+/HER2− and pT1b-2N01miM0 with predefined criteria. In our patient population, an absolute change in the final treatment decision occurred in 35% of cases. These results are similar to the results of other studies in the Spanish population where the change rate was 32%. 17 In the same way, the results of other studies conducted in European [19] [20] [21] and nonEuropean countries [22] [23] [24] [25] aligned with ours. The most relevant shift was from initial chemoendocrine therapy to hormonal treatment alone. First, a chemotherapy recommendation was advised in 56% of cases, but after the 21-gene RS assay, that recommendation was reduced to 25%. These results are similar to those presented by the cited studies.
Long-term studies have featured the use of the 21-gene RS assay as cost-effective. [26] [27] [28] Our results cannot be compared with those of cost-effectiveness studies because we used a short-term budget impact approach. In the Basque Health Service, the net cost per patient was €1,697 higher, in contrast to other studies that found the assay to be costsaving. 26, 27 A budget impact analysis carried out in Ireland found net savings explained by a much higher chemotherapy cost and percentage of change (59%). 29 This short-term impact relied on 2 drivers: percentage of treatment change and chemotherapy unit cost. The higher the percentage change in the treatment decision and the unit cost of chemotherapy, the more favorable the economic result of the 
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Dovepress Impact of the 21-gene recurrence score assay in the treatment of breast cancer test. Our results are consistent with the literature in which treatment was changed in approximately one third of cases after the use of the 21-gene RS test. [19] [20] [21] The figures for chemotherapy unit cost, however, vary significantly. Thus, Smyth et al applied a total cost of €7,903 in 2014 for each patient in Ireland treated with chemotherapy, including pharmacy and administration costs (€2,161), G-CSF with pegfilgrastim (€4,985), and adverse effects (€756). 29 The main difference between that study and ours is that currently the Basque Health Service uses drugs with a very low unit cost to stimulate the bone marrow. Our study followed the recommendation of experts for economic evaluations and applied 2 perspectives (societal and health system) that produced different results depending on the inclusion of specific stakeholders. 16 The interpretation of the shift from one perspective to the other is that maximizing the welfare of society could not always be consistent with the cost containment obtained by the health care sector. 16, 30 Application of a broader perspective by including the costs associated with the productivity losses produced a different conclusion. Chemotherapy-related sick leaves are long, as they last the duration of treatment, and avoiding treatment results in a €1,977 net saving per patient that offsets the test cost. Besides the sick leave, the consequences for the patients' quality of life must be considered. The reclassification avoided the chemotherapy-associated suffering, and thus, the patient's well-being was improved. However, we did not take into account either the costs associated with long-term side effects and potential metastasis or the long-term outcomes associated with the improved quality of life and potentially avoided recurrence due to improved treatment decisions.
As a strength, the present prospective study shows a large patient cohort (401 individuals with BC stages pN0 and pN1mi) in a small population area (2.2 million). A previous Spanish study analyzed a smaller cohort of 107 patients. In addition, patients analyzed with the 21-gene RS assay corresponded to the entire BC incident population of the participating hospitals. However, the patient cohort presents a limitation. The testing criteria established by the experts excluded 2 large groups of individuals. The patients with a more favorable prognosis and lower recurrence probability (T1a, T1b without high-risk features, and T1cG1 + low Ki-67) received hormonal treatment without other test evaluation, and the patients with a higher risk for recurrence (T2 + G3) who received chemotherapy directly also were not evaluated with the 21-gene RS test. Therefore, the test was applied to a patient pool with a questionable risk for cancer recurrence according to clinicopathologic classic criteria. By selecting those patients, we could, in fact, define the key target population for which the RS test reduced the uncertainty about chemotherapy decision making and therefore ensured its efficient use. The PR and Ki-67 levels are relevant variables in Prat's BC subclassification as luminal A and B subtypes. 11 The application of the 21-gene RS test modified significantly the relation between the clinical/histochemical characteristics and the probability of chemotherapy treatment. The results are consistent with the literature, indicating that a decreased level of progesterone and an increased Ki-67 level are associated with an increased long-term risk of cancer recurrence. 31 While Ki-67 was maintained as a significant variable in both scenarios, the roles of PR and tumor size were reversed in logistic regressions and ROC curves. In contrast with the study of Jasem et al, 25 we did not ascertain tumor size to be significant in predicting the prescription of chemotherapy when a 21-gene RS test was used. These findings reinforce the inclusion of patients with a large tumor size in the target population for 21-gene RS testing because a larger size does not mean a higher recurrence risk, if we adjust by a 21-gene RS. Abbreviations: AC, doxorubicin and cyclophosphamide; AC-Doc, doxorubicin and cyclophosphamide + docetaxel; AC-Pac, doxorubicin and cyclophosphamide + paclitaxel; chemo, chemotherapy; EC-Pac, epirubicin and cyclophosphamide + paclitaxel; FEC, fluorouracil (5FU), epirubicin, and cyclophosphamide; FEC-Doc, fluorouracil (5FU), epirubicin, and cyclophosphamide + docetaxel; TAC, docetaxel (Taxotere), doxorubicin (Adriamycin), and cyclophosphamide; TC, docetaxel (Taxotere) and cyclophosphamide.
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